Regenerative Medical Technology Group (RMTG) notifies late Q1 2026 10-Q filing

Rhea-AI Filing Summary

Regenerative Medical Technology Group Inc. submitted a Form NT 10-Q notifying the SEC of a late Quarterly Report for the period ended March 31, 2026. The company states it could not, without unreasonable effort or expense, timely compile required financial statements and expects to file within the five-day grace period allowed by Rule 12b-25. The notification is signed by David Christensen on May 15, 2026.

Key Figures

Form type: NT 10-Q Quarter end: March 31, 2026 Grace period: five-day grace period +3 more

6 metrics

Form type NT 10-Q Notification of late filing for the quarterly report

Quarter end March 31, 2026 Period covered by the delayed Quarterly Report

Grace period five-day grace period Relief under Rule 12b-25 for quarterly reports

SEC file number 000-56010 File number shown on the notification

Signature date May 15, 2026 Date the notice was signed by David Christensen

Telephone (800) 956-3935 Registrant contact number provided on the form

Key Terms

Rule 12b-25, Form 10-Q, five-day grace period

3 terms

Rule 12b-25 regulatory

"expects to file the Quarterly Report on or before the five-day grace period provided by Rule 12b-25"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q regulatory

"Quarterly Report on Form 10-Q for the quarter ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

five-day grace period regulatory

"on or before the five-day grace period provided by Rule 12b-25"

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SEC FILE NUMBER

000-56010

NOTIFICATION OF LATE FILING  

(Check One):	☐	Form 10-K	☐	Form 20-F	☐	Form 11-K	☒	Form 10-Q
	☐	Form 10-D	☐	Form N-SAR	☐	Form N-CSR

	For Period Ended: March 31, 2026
	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q
	☐	Transition Report on Form N-SAR
	For the Transition Period Ended: ___________________

Read Instructions (on back page) Before Preparing Form. Please Print or Type.

NOTHING IN THIS FORM SHALL BE CONSTRUED TO IMPLY THAT THE COMMISSION HAS VERIFIED ANY INFORMATION CONTAINED HEREIN.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Full Name of Registrant:	Regenerative Medical Technology Group Inc.
Former Name if Applicable:	n/a
Address of Principal Executive Offices (Street and Number):	433 Plaza Real Suite 275 Boca Raton, Florida 33432

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed (Check box if appropriate)

	(a)	The reasons described in reasonable detail in Part III of this form could not be eliminated without  unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12(b)-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The Registrant expects to file the Quarterly Report on or before the five-day grace period provided by Rule 12b-25.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification:

David Christensen		(800)		956-3935
Name		Area Code		Telephone Number

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes      ☒ No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2

Regenerative Medical Technology Group Inc.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 15, 2026	By:	/s/ David Christensen
		Name: David Christensen Title: President, Chief Executive Officer, Chief Financial Officer, Secretary and Director (Principal Executive Officer) (Principal Financial Officer) (Principal Accounting Officer)

Instruction: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001).

3

FAQ

Why did RMTG file a Form NT 10-Q?

RMTG filed the notice because it was unable to timely compile all financial statements and related disclosures for the Quarterly Report for the period ended March 31, 2026. The company cites unreasonable effort or expense as the reason and invoked Rule 12b-25 relief.

When does RMTG expect to file the delayed 10-Q?

The company expects to file the Quarterly Report on Form 10-Q on or before the five-day grace period provided by Rule 12b-25. The notification confirms the intent to use the five-calendar-day extension following the prescribed due date for the report.

Who signed the late-filing notification for RMTG?

The notification was signed by David Christensen, who is identified as President, Chief Executive Officer, Chief Financial Officer, Secretary and Director. The signature date shown on the form is May 15, 2026.

Does the notice say the delayed 10-Q will change prior results materially?

The form contains a question about anticipated significant changes in results, and the registrant answered No. The notification does not attach any quantitative or narrative estimate of material changes to results of operations for the period.